These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

669 related articles for article (PubMed ID: 11735645)

  • 1. Hepatotoxicity with thiazolidinediones: is it a class effect?
    Scheen AJ
    Drug Saf; 2001; 24(12):873-88. PubMed ID: 11735645
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thiazolidinediones and liver toxicity.
    Scheen AJ
    Diabetes Metab; 2001 Jun; 27(3):305-13. PubMed ID: 11431595
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thiazolidinedione hepatotoxicity: a class effect?
    Tolman KG
    Int J Clin Pract Suppl; 2000 Oct; (113):29-34. PubMed ID: 11965828
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of liver function in type 2 diabetic patients during clinical trials: evidence that rosiglitazone does not cause hepatic dysfunction.
    Lebovitz HE; Kreider M; Freed MI
    Diabetes Care; 2002 May; 25(5):815-21. PubMed ID: 11978674
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Troglitazone: the discovery and development of a novel therapy for the treatment of Type 2 diabetes mellitus.
    Parker JC
    Adv Drug Deliv Rev; 2002 Nov; 54(9):1173-97. PubMed ID: 12393300
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatotoxicity of the thiazolidinediones.
    Tolman KG; Chandramouli J
    Clin Liver Dis; 2003 May; 7(2):369-79, vi. PubMed ID: 12879989
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differentiating members of the thiazolidinedione class: a focus on safety.
    Lebovitz HE
    Diabetes Metab Res Rev; 2002; 18 Suppl 2():S23-9. PubMed ID: 11921435
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The development of thiazolidinedione drugs as anti-diabetic agents].
    Kuzuya T
    Nihon Rinsho; 2000 Feb; 58(2):364-9. PubMed ID: 10707559
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Troglitazone: a review of its use in the management of type 2 diabetes mellitus.
    Plosker GL; Faulds D
    Drugs; 1999 Mar; 57(3):409-38. PubMed ID: 10193691
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Thiazolidinediones: clinical data and perspectives].
    Blicklé JF
    Diabetes Metab; 2001 Apr; 27(2 Pt 2):279-85. PubMed ID: 11452222
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thiazolidinediones for type 2 diabetes. New agents reduce insulin resistance but need long term clinical trials.
    Krentz AJ; Bailey CJ; Melander A
    BMJ; 2000 Jul; 321(7256):252-3. PubMed ID: 10915108
    [No Abstract]   [Full Text] [Related]  

  • 12. Promising new approaches.
    Reasner CA
    Diabetes Obes Metab; 1999 May; 1 Suppl 1():S41-8. PubMed ID: 11220287
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rosiglitazone: a review of its use in the management of type 2 diabetes mellitus.
    Wagstaff AJ; Goa KL
    Drugs; 2002; 62(12):1805-37. PubMed ID: 12149047
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Second-generation thiazolidinediones and hepatotoxicity.
    Marcy TR; Britton ML; Blevins SM
    Ann Pharmacother; 2004 Sep; 38(9):1419-23. PubMed ID: 15266041
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Two cases of severe clinical and histologic hepatotoxicity associated with troglitazone.
    Gitlin N; Julie NL; Spurr CL; Lim KN; Juarbe HM
    Ann Intern Med; 1998 Jul; 129(1):36-8. PubMed ID: 9652997
    [No Abstract]   [Full Text] [Related]  

  • 16. Comparison of effects of thiazolidinediones on cardiovascular risk factors: observations from a clinical practice.
    Gegick CG; Altheimer MD
    Endocr Pract; 2001; 7(3):162-9. PubMed ID: 11421562
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Troglitazone in type II diabetes mellitus.
    Sparano N; Seaton TL
    Pharmacotherapy; 1998; 18(3):539-48. PubMed ID: 9620105
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Glitazones. Profile of a new class of substances].
    Janka HU
    Internist (Berl); 2001 Apr; 42(4):587-96. PubMed ID: 11326741
    [No Abstract]   [Full Text] [Related]  

  • 19. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lessons from the glitazones: a story of drug development.
    Gale EA
    Lancet; 2001 Jun; 357(9271):1870-5. PubMed ID: 11410214
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.